§
Luxuse
Patent Intelligence
Sign In
Patent EP0665015A2 successfully refreshed from Google Patents.
← Back to Patent Explorer
EP0665015A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

Combination treatment for osteoporosis

Assignee: Eli Lilly and Co
•
Filing: 1995-01-25
•
Granted: —
•
Expires: 2015-01-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract This invention provides a new method for treating osteoporosis comprising administering : 1) a compound of formula I wherein R and R 1 , independently, are hydrogen, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy-C 2 -C 6 -acyloxy, R 2- substituted aryloxy, R 2- substituted aroyloxy, R 3- substituted carbonyloxy or halo ; R 2 is C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, hydrogen or halo ; and R 3 is C 1 -C 6 -alkoxy or aryloxy ; n is 2, 3 or 4 ; and p is 4, 5 or 6 ; or a pharmaceutically acceptable salt or solvate thereof ; together with 2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in amounts such that the combination retains or increases bone density. The invention also provides pharmaceutical formulations for inhibiting bone loss comprising (1) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof; and (2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in amounts such that the combination inhibits bone loss, together with one or more pharmaceutically acceptable carriers.

Inventors

  • 👤 Larry John Black
  • 👤 George Joseph Cullinan

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-10-23 18:56
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/4535; A61K31/56; A61K31/565; A61K31/40; A61K31/4025; A61K31/55; A61K31/57; A61P; A61P19/00; A61P19/08; A61P19/10; A61P43/00; C; C07; C07D; C07D409/00; C07D409/02; C07D409/10

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 133 words
The use of: 1) a compound of formula I wherein Rand R 1 , independently, are hydrogen, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy-C 2 -C 6 -acyloxy, R 2- substituted aryloxy, R 2- substituted aroyloxy, R 3- substituted carbonyloxy or halo; R 2 is C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, hydrogen or halo; and R 3 is C 1 -C 6 -alkoxy or aryloxy; n is 2, 3 or 4; and p is 4, 5 or 6; or a pharmaceutically acceptable salt or solvate thereof; together with 2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in the preparation of a medicament useful for retaining or increasing bone density, or inhibiting bone loss.
Claim 2
Dependent Claim 133 words
The use of: 1) a compound of formula I wherein Rand R 1 , independently, are hydrogen, hydroxyl, C 1 -C 6 -alkoxy, C 1 -C 6 acyloxy, C 1 -C 6 alkoxy-C 2 -C 6 -acyloxy, R 2- substituted aryloxy, R 2- substituted aroyloxy, R 3- substituted carbonyloxy or halo; R 2 is C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, hydrogen or halo; and R 3 is C 1 -C 6 -alkoxy or aryloxy; n is 2, 3 or 4; and p is 4, 5 or 6; or a pharmaceutically acceptable salt or solvate thereof; together with 2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in the preparation of a medicament useful for retaining or increasing bone density, or inhibiting bone loss.
Claim 3
Dependent Claim 35 words
The use of Claim 2 wherein the formula I compound is one in which R and R 1 are hydroxyl, n is 2 and p is 4 or 5; and the selected progestin is norethindrone.
Claim 4
Dependent Claim 17 words
The use of Claim 3 wherein the formula I compound is one in which p is 5.
Claim 5
Dependent Claim 25 words
The use of Claim 2 wherein R and R 1 are hydroxyl, n is 2 and p is 5; and the selected progestin is norethynodrel.
Claim 6
Dependent Claim 41 words
The use of Claim 1 wherein the amount of formula I compound administered is from 0.1 to about 1000 mg/kg of body weight and the amount of selected progestin administered is from about 0.01 to about 500 mg/kg of body weight.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag